A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

This trial tests whether EB-1020 — an investigational once-daily extended-release capsule — is effective and safe for treating attention-deficit/hyperactivity disorder (ADHD) in children. Two different doses of EB-1020 will be compared, and researchers will measure changes in ADHD symptoms and overall severity. Children with a confirmed primary ADHD diagnosis (based on DSM-5 criteria), a symptom score above a defined threshold on the ADHD Rating Scale, and a severity rating of 4 or higher on clinical assessment are eligible; children with certain other psychiatric conditions, suicidal ideation, autism spectrum disorder, or substance use disorder are excluded. Participation involves taking the study capsule once daily and attending regular clinic visits for symptom rating and safety monitoring. This summary was generated with AI assistance and is intended to help patients understand the study in plain language.